GlassScriptPhysician profile
Jeffrey R Mindel
NPI 1821133091
$6,994.08
in general payments reported to CMS, 2019-2025
53 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $962 · 2021: $1,081 · 2022: $796 · 2023: $1,036 · 2024: $1,049 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $632.82 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $451.53 | 2019-2025 | |
| Amgen INC. | $425.34 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $388.97 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Abbvie INC. | $368.33 | 2019-2025 | |
| Radius Health, INC. | $344.63 | 2019-2025 | Tymlos |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Corcept Therapeutics | $320.58 | 2019-2025 | Korlym |
| Lilly USA, LLC | $255.80 | 2019-2025 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $245.60 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $238.08 | 2020-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $230.41 | 2019-2025 | Strensiq |
| Insulet Corporation | $228.86 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $169.73 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $163.75 | 2019-2024 | Afrezza |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $152.81 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $146.95 | 2021-2025 | |
| Horizon Therapeutics Plc | $137.34 | 2020-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.67 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Becton, Dickinson and Company | $114.23 | 2019-2022 | |
| Medtronic, INC. | $110.93 | 2022-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $95.28 | 2021-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $90.62 | 2019-2023 | Farxiga |
| Recordati_rare_diseases_inc. | $87.15 | 2021-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $79.61 | 2020-2023 | |
| Ibsa Pharma INC. | $78.77 | 2020-2024 | Tirosint, Licart, Tirosint |
| Genzyme Corporation | $72.00 | 2020 | |
| Lifescan, INC. | $71.63 | 2019-2022 | |
| Almatica Pharma LLC | $70.37 | 2024-2025 | Teriparatide, Loreev Xr |
| Janssen Pharmaceuticals, INC | $53.18 | 2019-2020 | |
| Averitas Pharma INC. | $50.39 | 2024 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $43.70 | 2020-2021 | |
| Kyowa Kirin, INC. | $43.51 | 2023 | Crysvita |
| Ascensia Diabetes Care US INC. | $43.08 | 2022-2023 | |
| Zealand Pharma US, INC. | $41.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $39.06 | 2019 | |
| Sequel Med Tech, LLC | $38.19 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $35.85 | 2022-2023 | |
| Medtronic Minimed, INC. | $35.63 | 2019-2020 | |
| Dexcom, INC. | $34.02 | 2019-2021 | |
| Beta Bionics, INC. | $31.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $29.41 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2021 | |
| Embecta Corp. | $27.76 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $27.08 | 2019-2020 | |
| Pfizer INC. | $25.54 | 2025 | |
| Soleno Therapeutics, INC. | $24.84 | 2025 | Vykat Xr |
| Shire North American Group INC | $23.56 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.55 | 2023 | |
| Nevro Corp. | $22.26 | 2023 | Senza |
| Halozyme INC | $20.26 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.64 | 2023 | Adthyza |
| Tolmar, INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.